G1043

Guanfacine hydrochloride

≥98% (HPLC)

• Synonim(y): N (Aminoiminomethyl)-2,6-dichlorobenzeneacetamide
• Wzór empiryczny (zapis Hilla): C₉H₉Cl₂N₃O · HCl
• Numer CAS: 29110-48-3
• Masa cząsteczkowa: 282.55
• NACRES: NA.77
• PubChem Substance ID: 24278452
• UNSPSC Code: 12352200
• MDL number: MFCD00798230
• Assay: ≥98% (HPLC)

Właściwości

• Quality Segment: 100
• assay: ≥98% (HPLC)
• color: white
• solubility: H₂O: soluble 12 mg/mL at 60 °C
• originator: Promius
• SMILES string: Cl.NC(=N)NC(=O)Cc1c(Cl)cccc1Cl
• InChI: 1S/C9H9Cl2N3O.ClH/c10-6-2-1-3-7(11)5(6)4-8(15)14-9(12)13;/h1-3H,4H2,(H4,12,13,14,15);1H
• InChI key: DGFYECXYGUIODH-UHFFFAOYSA-N
• Gene Information: human ... ADRA2A(150), ADRA2B(151), ADRA2C(152)

Opis

Application

Guanfacine hydrochloride has been used as an α2A adrenoceptor agonist to test its protective effect on hypobaric hypoxia (HH) and in rat brain to measure blood oxygenation level dependent (BOLD) response.

Biochem/physiol Actions

α-2 noradrenergic receptor agonist.

Guanfacine stimulates the brain postsynaptic α2 adrenergic receptor (AR) and mediates the prefrontal cortical (PFC) neuronal regulation and strengthens their network. Guanfacine improves the density of neuronal dendrites and is useful in treating neuropsychiatric disorders. It modulates the synaptic and cytoskeletal proteins expression in prefrontal cortical (PFC) neurons and may improve hypobaric hypoxia (HH) induced PFC dysfunctions. Guanfacine enhances cognitive function and is recommended for attention deficit hyperactivity disorder (ADHD) therapy.

Features and Benefits

This compound was developed by Promius. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Ta strona może zawierać tekst przetłumaczony maszynowo.

Informacja o środkach bezpieczeństwa

• Klasa składowania: 11 - Combustible Solids
• wgk: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable
• ppe: Eyeshields, Gloves, type N95 (US)